Key result
Direct stenting with the Skylor stent was associated with fewer major adverse cardiac events compared to predilation.
Why the study?
Does direct coronary stenting reduce major adverse cardiac events compared to stenting following pre-dilation in patients receiving the Skylor bare-metal stent?
Observational (n=1,020)
Yes
Does direct coronary stenting reduce major adverse cardiac events compared to stenting following pre-dilation in patients receiving the Skylor bare-metal stent?
Direct stenting with the thin-strut cobalt-chromium Skylor bare-metal stent is associated with a lower risk of long-term major adverse cardiac events compared to stenting after pre-dilation.
Answers are grounded in this paper and cite their sources.
May favor direct stenting with Skylor BMS; hypothesis-generating and leaves open need for randomized confirmation.
BACKGROUND: Despite significant improvements in stent platform, currently available bare-metal stents (BMS) are still associated with restenosis. Thin-strut design cobalt-chromium alloys hold the promise of improving results of BMS, especially when implanted with direct technique. We performed an observational study to appraise outcomes of the novel Skylor™ stent, stratifying outcomes according to stenting technique. METHODS AND RESULTS: We included all consecutive patients undergoing coronary stenting with Skylor™ at 2 centers between 2006 and 2009. The primary end-point was the long-term rate of major adverse cardiac events (MACE, i.e. death, myocardial infarction (MI), coronary artery bypass grafting (CABG) or target vessel revascularization (TVR)). As pre-specified analysis, we compared patients undergoing direct stenting versus those stent implantation following predilation. A total of 1020 patients were included (1292 Skylor™ stents), with procedural success obtained in 99%. Comparing patients undergoing direct stenting (66%) versus pre-dilation (34%) at 16±7 months of follow-up, MACE had occurred in, respectively, 8% versus 14% (p=0.001), with death in 1% versus 2= (p=0.380), MI in 1% versus 2% (p=0.032), CABG in 0.2% versus 2% (p=0.012), and TVR in 6% versus 9% [p=0.071]. Even at multivariable analysis with propensity adjustment, direct stenting was associated with significantly fewer MACE [hazard ratio 0.60 [0.38-0.93], p=0.024]. CONCLUSIONS: This observational study suggests the presence of a beneficial synergy between direct coronary stenting technique and use of the novel thin-strut cobalt-chromium Skylor™ stent in real-world patients undergoing PCI.
No takes yet. Share an insight, caveat, or question.
Giordano et al. (2012) conducted an observational in coronary artery disease requiring stenting (n=1,020). Direct stenting vs. Stent implantation following predilation was evaluated on long-term rate of major adverse cardiac events (MACE, i.e. death, myocardial infarction, coronary artery bypass grafting or target vessel revascularization) (HR 0.60, 95% CI 0.38-0.93, p=0.024). Direct stenting with the Skylor stent was associated with fewer major adverse cardiac events compared to predilation.
Synapse has enriched 10 related papers. Consider them for comparative context: